Irinotecan liposome and ivonescimab for second-line small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (irinotecan liposome and ivonescimab) for people with advanced small cell lung cancer whose first treatment (chemotherapy with or without immunotherapy) stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced small cell lung cancer that got worse after first-line platinum-based chemotherapy (with or without checkpoint inhibitors).
- You are able to get around and take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans (and hasn't been radiated in the last 6 months).
- Brain metastases, if any, are treated and stable for at least 1 month, or you have none.
- You have adequate organ function (kidneys, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs (adebelizumab and irinotecan liposome) for people with advanced small cell lung cancer that got worse after first-line treatment. It aims to see if this combination works better and to find out which patients benefit the most.
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Hear when a new SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.